MiRXES
MiRXES is a Singapore-headquartered biotechnology company.
Mirxes reports $95.4m net loss ahead of IPO
Mirxes reports $95.4m net loss ahead of IPO
Costs of R&D and administrative activities widened last year’s losses.
Read Here
Advertise
Sign Up
Commentary
In the age of AI, creativity is the decisive advantage
Hong Kong cleared stablecoins for take-off. Getting them to work across Asia is the hard part
Why Hong Kong’s retail product reshuffle may favour large suppliers